(SGHC) SGHC - Overview
Stock: Sports Betting, Online Casino
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 4.36% |
| Yield on Cost 5y | 4.35% |
| Yield CAGR 5y | -36.00% |
| Payout Consistency | 86.9% |
| Payout Ratio | 138.7% |
| Risk 5d forecast | |
|---|---|
| Volatility | 50.2% |
| Relative Tail Risk | -10.7% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.44 |
| Alpha | -3.64 |
| Character TTM | |
|---|---|
| Beta | 1.038 |
| Beta Downside | 0.924 |
| Drawdowns 3y | |
|---|---|
| Max DD | 36.06% |
| CAGR/Max DD | 1.01 |
Description: SGHC SGHC January 09, 2026
Super Group (SGHC) Limited (NYSE: SGHC) is an online sports betting and gaming operator headquartered in Saint Peter Port, Guernsey. Its flagship brands are Betway, which combines sports betting with a casino platform, and Spin, a multi-brand online casino. The company’s footprint spans Africa, the Middle East, Asia-Pacific, Europe, North America, and South/Latin America, giving it exposure to both emerging and mature regulated markets.
Key operating metrics (2023 FY): Revenue of roughly $1.2 billion, an EBITDA margin of ~12 %, and an active registered user base exceeding 30 million, with mobile users accounting for about 70 % of traffic. The online gambling sector is projected to grow at a CAGR of ~10 % through 2029, driven by rising internet penetration, liberalization of betting regulations in the U.S. and Europe, and increasing consumer discretionary spending on digital entertainment.
Strategic considerations: SGHC’s diversified geographic mix mitigates reliance on any single jurisdiction, but regulatory risk remains material-particularly in markets where licensing frameworks are evolving. Additionally, the company’s ability to monetize its user base through cross-sell of sports betting and casino products is a critical lever for margin expansion.
For a deeper quantitative analysis of SGHC’s valuation and peer dynamics, the ValueRay platform offers a concise, data-driven overview worth exploring.
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income: 200.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.17 > 0.02 and ΔFCF/TA 9.49 > 1.0 |
| NWC/Revenue: 14.25% < 20% (prev 9.59%; Δ 4.66% < -1%) |
| CFO/TA 0.25 > 3% & CFO 295.1m > Net Income 200.1m |
| Net Debt (-397.0m) to EBITDA (294.2m): -1.35 < 3 |
| Current Ratio: 1.75 > 1.5 & < 3 |
| Outstanding Shares: last quarter (508.5m) vs 12m ago 1.01% < -2% |
| Gross Margin: 52.41% > 18% (prev 0.43%; Δ 5198 % > 0.5%) |
| Asset Turnover: 174.8% > 50% (prev 149.4%; Δ 25.33% > 0%) |
| Interest Coverage Ratio: 40.51 > 6 (EBITDA TTM 294.2m / Interest Expense TTM 6.05m) |
Altman Z'' 5.81
| A: 0.24 (Total Current Assets 665.0m - Total Current Liabilities 380.0m) / Total Assets 1.19b |
| B: 0.33 (Retained Earnings 388.0m / Total Assets 1.19b) |
| C: 0.21 (EBIT TTM 245.3m / Avg Total Assets 1.14b) |
| D: 1.66 (Book Value of Equity 748.0m / Total Liabilities 450.0m) |
| Altman-Z'' Score: 5.81 = AAA |
Beneish M -3.30
| DSRI: 0.89 (Receivables 180.0m/165.7m, Revenue 2.00b/1.64b) |
| GMI: 0.82 (GM 52.41% / 42.98%) |
| AQI: 0.84 (AQ_t 0.35 / AQ_t-1 0.42) |
| SGI: 1.22 (Revenue 2.00b / 1.64b) |
| TATA: -0.08 (NI 200.1m - CFO 295.1m) / TA 1.19b) |
| Beneish M-Score: -3.30 (Cap -4..+1) = AA |
What is the price of SGHC shares?
Over the past week, the price has changed by -1.19%, over one month by -19.41%, over three months by -20.09% and over the past year by +14.61%.
Is SGHC a buy, sell or hold?
- StrongBuy: 5
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the SGHC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 17.6 | 93.5% |
| Analysts Target Price | 17.6 | 93.5% |
| ValueRay Target Price | 9.5 | 4.6% |
SGHC Fundamental Data Overview February 05, 2026
P/E Trailing = 22.0732
P/E Forward = 11.4416
P/S = 1.9531
P/B = 6.3663
Revenue TTM = 2.00b EUR
EBIT TTM = 245.3m EUR
EBITDA TTM = 294.2m EUR
Long Term Debt = 16.0m EUR (from longTermDebt, last quarter)
Short Term Debt = 5.00m EUR (from shortTermDebt, last quarter)
Debt = 72.0m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = -397.0m EUR (from netDebt column, last quarter)
Enterprise Value = 3.46b EUR (3.88b + Debt 72.0m - CCE 485.0m)
Interest Coverage Ratio = 40.51 (Ebit TTM 245.3m / Interest Expense TTM 6.05m)
EV/FCF = 17.35x (Enterprise Value 3.46b / FCF TTM 199.6m)
FCF Yield = 5.76% (FCF TTM 199.6m / Enterprise Value 3.46b)
FCF Margin = 9.98% (FCF TTM 199.6m / Revenue TTM 2.00b)
Net Margin = 10.01% (Net Income TTM 200.1m / Revenue TTM 2.00b)
Gross Margin = 52.41% ((Revenue TTM 2.00b - Cost of Revenue TTM 951.6m) / Revenue TTM)
Gross Margin QoQ = 33.39% (prev 29.19%)
Tobins Q-Ratio = 2.90 (Enterprise Value 3.46b / Total Assets 1.19b)
Interest Expense / Debt = 1.39% (Interest Expense 1.00m / Debt 72.0m)
Taxrate = 27.82% (31.5m / 113.3m)
NOPAT = 177.1m (EBIT 245.3m * (1 - 27.82%))
Current Ratio = 1.75 (Total Current Assets 665.0m / Total Current Liabilities 380.0m)
Debt / Equity = 0.10 (Debt 72.0m / totalStockholderEquity, last quarter 745.0m)
Debt / EBITDA = -1.35 (Net Debt -397.0m / EBITDA 294.2m)
Debt / FCF = -1.99 (Net Debt -397.0m / FCF TTM 199.6m)
Total Stockholder Equity = 658.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 17.49% (Net Income 200.1m / Total Assets 1.19b)
RoE = 30.38% (Net Income TTM 200.1m / Total Stockholder Equity 658.8m)
RoCE = 36.35% (EBIT 245.3m / Capital Employed (Equity 658.8m + L.T.Debt 16.0m))
RoIC = 26.71% (NOPAT 177.1m / Invested Capital 662.8m)
WACC = 9.58% (E(3.88b)/V(3.95b) * Re(9.74%) + D(72.0m)/V(3.95b) * Rd(1.39%) * (1-Tc(0.28)))
Discount Rate = 9.74% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.05%
[DCF Debug] Terminal Value 76.30% ; FCFF base≈151.5m ; Y1≈186.9m ; Y5≈318.3m
Fair Price DCF = 8.83 (EV 4.07b - Net Debt -397.0m = Equity 4.46b / Shares 505.6m; r=9.58% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 37.02 | EPS CAGR: 174.1% | SUE: 0.61 | # QB: 0
Revenue Correlation: 91.16 | Revenue CAGR: 9.77% | SUE: 0.51 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.15 | Chg30d=+0.000 | Revisions Net=+1 | Analysts=1
EPS next Year (2026-12-31): EPS=0.72 | Chg30d=-0.008 | Revisions Net=+1 | Growth EPS=+59.2% | Growth Revenue=+10.2%